Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + chemotherapy for first-line treatment of pulmonary neuroendocrine carcinoma (Phase II, single-arm, China)
ChiCTR2500113228Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of serplulimab in Lung neuroendocrine carcinoma (LNEC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Objective Response Rate (ORR). Started Nov 2025; status: recruiting.
02
Drugs
serplulimab
03
Conditions
Lung neuroendocrine carcinoma (LNEC)
Beyond the preview
Go deeper on ChiCTR2500113228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113228.